Articles producció científica> Ciències Mèdiques Bàsiques

Study of Liquid-Based Cytology Using Next-Generation Sequencing as a Liquid Biopsy Application in Patients with Advanced Oncological Disease

  • Identification data

    Identifier: imarina:9325522
    Authors:
    Pena, KBRiu, FHernandez, AGuilarte, CElizalde-Horcada, MParada, D
    Abstract:
    In patients with advanced cancer, it is necessary to detect driver mutations and genetic arrangements. If a mutation is found, targeted therapy may become an option. However, in most patients with advanced cancer, obtaining material can be challenging, and these determinations must be made based on small biopsies or cytologic samples. We analyzed the ability of liquid-based cytology to determine the mutational status in patients with advanced cancer by next-generation sequencing. We studied cytologic samples from 28 patients between 1 January 2018 and 31 December 2022. All samples were processed by next-generation sequencing using the Oncomine(& REG;) Precision and Comprehensive Assay Panels for Solid Tumors. Eleven male and 17 female patients with a median age of 63.75 years were included. Clinical stage IV was predominant in 21 patients. Eleven patients died, and 17 survived. The DNA and RNA concentrations were 10.53 ng/& mu;L and 13 ng/& mu;L, respectively. Eleven patients showed actionable mutations, and 17 showed other genomic alterations. Liquid-based cytology can be used as a component of liquid biopsy, as it allows the identification of actionable mutations in patients with advanced oncological disease. Our findings expand the utility of liquid biopsy from different body fluids or cell aspirates.
  • Others:

    Author, as appears in the article.: Pena, KB; Riu, F; Hernandez, A; Guilarte, C; Elizalde-Horcada, M; Parada, D
    Department: Ciències Mèdiques Bàsiques
    URV's Author/s: Parada Dominguez, David / Peña Gonzalez, Karla Beatriz / Riu Ferrando, Francisco Pedro
    Keywords: Precision Mutation Medicine Liquid-based Cytology Cell lung-cancer Cancer Alpelisib Actionable
    Abstract: In patients with advanced cancer, it is necessary to detect driver mutations and genetic arrangements. If a mutation is found, targeted therapy may become an option. However, in most patients with advanced cancer, obtaining material can be challenging, and these determinations must be made based on small biopsies or cytologic samples. We analyzed the ability of liquid-based cytology to determine the mutational status in patients with advanced cancer by next-generation sequencing. We studied cytologic samples from 28 patients between 1 January 2018 and 31 December 2022. All samples were processed by next-generation sequencing using the Oncomine(& REG;) Precision and Comprehensive Assay Panels for Solid Tumors. Eleven male and 17 female patients with a median age of 63.75 years were included. Clinical stage IV was predominant in 21 patients. Eleven patients died, and 17 survived. The DNA and RNA concentrations were 10.53 ng/& mu;L and 13 ng/& mu;L, respectively. Eleven patients showed actionable mutations, and 17 showed other genomic alterations. Liquid-based cytology can be used as a component of liquid biopsy, as it allows the identification of actionable mutations in patients with advanced oncological disease. Our findings expand the utility of liquid biopsy from different body fluids or cell aspirates.
    Thematic Areas: Pharmacology & pharmacy Medicine, research & experimental Medicine (miscellaneous) General biochemistry,genetics and molecular biology Ciencias sociales Biochemistry, genetics and molecular biology (miscellaneous) Biochemistry, genetics and molecular biology (all) Biochemistry & molecular biology
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: franciscopedro.riu@urv.cat karlabeatriz.pena@urv.cat david.parada@urv.cat
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2227-9059/11/6/1578
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Biomedicines. 11 (6):
    APA: Pena, KB; Riu, F; Hernandez, A; Guilarte, C; Elizalde-Horcada, M; Parada, D (2023). Study of Liquid-Based Cytology Using Next-Generation Sequencing as a Liquid Biopsy Application in Patients with Advanced Oncological Disease. Biomedicines, 11(6), -. DOI: 10.3390/biomedicines11061578
    Article's DOI: 10.3390/biomedicines11061578
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Biochemistry & Molecular Biology,Biochemistry, Genetics and Molecular Biology (Miscellaneous),Medicine (Miscellaneous),Medicine, Research & Experimental,Pharmacology & Pharmacy
    Precision
    Mutation
    Medicine
    Liquid-based
    Cytology
    Cell lung-cancer
    Cancer
    Alpelisib
    Actionable
    Pharmacology & pharmacy
    Medicine, research & experimental
    Medicine (miscellaneous)
    General biochemistry,genetics and molecular biology
    Ciencias sociales
    Biochemistry, genetics and molecular biology (miscellaneous)
    Biochemistry, genetics and molecular biology (all)
    Biochemistry & molecular biology
  • Documents:

  • Cerca a google

    Search to google scholar